NRX Pharmaceuticals Q2 2025 Update: Revenue Flat, Assets Shift

TL;DR

**NRXP Q2 2025: Revenue flat at $0.001M, assets $19.5M vs $14.6M LY. 50M common shares.**

AI Summary

NRX Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2025. The company reported $0.001 in revenue for the six months ended June 30, 2025, compared to $0.001 for the same period in 2024. Total assets were $19,473,588 as of June 30, 2025, a decrease from $14,591,505 as of December 31, 2024. The company had 50,000,000 shares of common stock authorized.

Why It Matters

This filing provides a snapshot of NRX Pharmaceuticals' financial health and operational status for the second quarter of 2025, impacting investor confidence and future strategic decisions.

Risk Assessment

Risk Level: medium — The company's low revenue and significant asset fluctuations suggest potential financial instability and operational challenges.

Key Numbers

• $0.001 — Revenue (6 months ended 06/30/2025) (Indicates minimal sales activity.)
• $19,473,588 — Total Assets (06/30/2025) (Represents the company's total resources.)
• 50,000,000 — Authorized Common Stock (Indicates the maximum number of shares the company can issue.)

Key Players & Entities

• NRX Pharmaceuticals, Inc. (company) — Filer
• June 30, 2025 (date) — Reporting Period End Date
• $0.001 (dollar_amount) — Revenue for six months ended June 30, 2025
• $19,473,588 (dollar_amount) — Total assets as of June 30, 2025
• $14,591,505 (dollar_amount) — Total assets as of December 31, 2024
• 50,000,000 (dollar_amount) — Authorized shares of common stock

FAQ

Key Financial Figures

• $0.001 — h registered: Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar

Filing Documents

• nrxp20250630_10q.htm (10-Q) — 1583KB
• ex_847161.htm (EX-31.1) — 18KB
• ex_847160.htm (EX-31.2) — 18KB
• ex_847159.htm (EX-32.1) — 5KB
• ex_847158.htm (EX-32.2) — 5KB
• g01.jpg (GRAPHIC) — 40KB
• g02.jpg (GRAPHIC) — 30KB
• image1.jpg (GRAPHIC) — 42KB
• image2.jpg (GRAPHIC) — 29KB
• 0001437749-25-027167.txt ( ) — 8902KB
• nrxp-20250630.xsd (EX-101.SCH) — 74KB
• nrxp-20250630_cal.xml (EX-101.CAL) — 33KB
• nrxp-20250630_def.xml (EX-101.DEF) — 533KB
• nrxp-20250630_lab.xml (EX-101.LAB) — 432KB
• nrxp-20250630_pre.xml (EX-101.PRE) — 561KB
• nrxp20250630_10q_htm.xml (XML) — 1337KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION ITEM 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 3 Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 4 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Deficit for the three and six months ended June 30, 2025 and 2024 5 Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 32 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 43 ITEM 4.

Controls and Procedures

Controls and Procedures 44

- OTHER INFORMATION

PART II - OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 44 ITEM 1A.

Risk Factors

Risk Factors 45 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 45 ITEM 3. Defaults Upon Senior Securities 46 ITEM 4. Mine Safety Disclosures 46 ITEM 5. Other Information 46 ITEM 6. Exhibits 46

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION

Financial Statements

ITEM 1. Financial Statements NRX PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) June 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 2,910 $ 1,443 Prepaid expenses and other current assets 1,680 1,859 Total current assets 4,590 3,302 Other assets 248 349 Total assets $ 4,838 $ 3,651 LIABILITIES AND STOCKHOLDERS ' DEFICIT Current liabilities: Accounts payable $ 3,630 $ 4,130 Accrued and other current liabilities 9,974 10,149 Accrued clinical site costs 351 379 Convertible note payable and accrued interest – short term 9,854 1,246 Insurance loan payable 378 320 Warrant liabilities 16,266 5,639 Total current liabilities 40,453 21,863 Convertible note payable and accrued interest – long term — 5,011 Total liabilities $ 40,453 $ 26,874 Commitments and Contingencies (Note 8) Stockholders' deficit: Preferred stock, $ 0.001 par value, 50,000,000 shares authorized; $ — $ — Series A convertible preferred stock, $ 0.001 par value, 12,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.001 par value, 500,000,000 shares authorized; 19,473,588 and 14,591,505 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 19 15 Additional paid-in capital 265,732 255,035 Accumulated deficit ( 301,366 ) ( 278,273 ) Total stockholders' deficit ( 35,615 ) ( 23,223 ) Total liabilities and stockholders' deficit $ 4,838 $ 3,651 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 NRX PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (Unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Operating expense: Research and development

View Full Filing

View this 10-Q filing on SEC EDGAR